Department of Psychiatry, Taipei Veterans General Hospital, Hualien City, Taiwan.
Institute of Medical Sciences, Tzu Chi University, Hualien City, Taiwan.
PLoS One. 2020 Nov 30;15(11):e0242975. doi: 10.1371/journal.pone.0242975. eCollection 2020.
In this population-based propensity score matched (PSM) cohort study, we aimed to investigate the risk of developing dementia with the use of acid suppressants, including proton pump inhibitors (PPIs) and histamine-2 receptor antagonists (H2 antagonists). Cohorts of PPI users (n = 2,778), H2 antagonist users (n = 6,165), and non-users (n = 86,238) were selected from a dataset covering the years 2000 to 2010 in Taiwan's National Health Insurance Research Database. Patients in the three groups were PSM at a ratio of 1:1 within each comparison cohort (CC). Three CCs were created: (1) PPI users compared to non-users (CC1, n = 2,583 pairs); (2) H2 antagonist users compared to non-users (CC2, n = 5,955 pairs); and (3) PPI users compared to H2 antagonist users (CC3, n = 2,765 pairs). A multivariable robust Cox proportional hazard model was used to estimate the adjusted hazard ratio (aHR) and the 95% confidence interval (CI) for the risk of developing dementia. The multivariable analysis results show that the aHR of developing dementia during the follow-up period was 0.72 (CC1: 95% CI = 0.51-1.03, P = 0.07) for PPI users and 0.95 (CC2: 95% CI = 0.74-1.22, P = 0.69) for H2 antagonist users, when compared to non-users. Between the patients using acid suppressants, there was no difference between PPI and H2 antagonist users in the risk of developing dementia (CC3: aHR = 0.82, 95% CI = 0.58-1.17, P = 0.28). In conclusion, no association was observed between the use of acid suppressants and the risk of developing dementia in any of the three CCs. Further, randomized controlled trials are warranted to confirm this relationship.
在这项基于人群的倾向评分匹配(PSM)队列研究中,我们旨在研究使用酸抑制剂(包括质子泵抑制剂[PPI]和组胺-2 受体拮抗剂[H2 拮抗剂])与痴呆发展风险之间的关系。从台湾全民健康保险研究数据库涵盖 2000 年至 2010 年的数据集中选择了 PPI 用户(n = 2778)、H2 拮抗剂用户(n = 6165)和非使用者(n = 86238)队列。在每个比较队列(CC)内,将三组患者以 1:1 的比例进行 PSM。创建了三个 CC:(1)PPI 用户与非使用者比较(CC1,n = 2583 对);(2)H2 拮抗剂使用者与非使用者比较(CC2,n = 5955 对);(3)PPI 用户与 H2 拮抗剂使用者比较(CC3,n = 2765 对)。使用多变量稳健 Cox 比例风险模型估计了痴呆发生风险的调整后风险比(aHR)和 95%置信区间(CI)。多变量分析结果表明,在随访期间,与非使用者相比,PPI 使用者发生痴呆的 aHR 为 0.72(CC1:95%CI=0.51-1.03,P=0.07),H2 拮抗剂使用者为 0.95(CC2:95%CI=0.74-1.22,P=0.69)。在使用酸抑制剂的患者中,PPI 和 H2 拮抗剂使用者在发生痴呆的风险方面没有差异(CC3:aHR=0.82,95%CI=0.58-1.17,P=0.28)。总之,在任何一个 CC 中,酸抑制剂的使用与痴呆的发病风险之间均无关联。需要进一步的随机对照试验来证实这种关系。